Synonyms: example 1 [WO2016094821A2]
rezivertinib is an approved drug
Compound class:
Synthetic organic
Comment: The chemical structure submitted to the WHO for INN rezivertinib, is identical to the structure of example 1 that is claimed in patent WO2016094821A2 by Beta Pharma [1]. This patent claims novel EGFR inhibitors that are active against mutated EGFRs that are found in cancers, i.e. third generation EGFR inhibitors. From Beta Pharma's declared pipeline, example 1 is likely to be BPI-7711, which is being investigated for the treatment of EGFRT790M-mutant non-small cell lung cancer. We await formal name>structure confirmation. Experimental evidence in WO2016094821A2 indicates that example 1 is orally bioavailable.
|
|
Bioactivity Comments |
Example 1 exhibits anti-proliferative activity in vitro and in vivo (in mice with HCC827 and H1975 cell xenograft tumours) [1]. HCC827 cells harbour an EGFR with E746-A750 deletion; H1975 cells express the L858R/T790M double mutation). The in vitro anti-proliferative effect of example 1 is more pronounced in H1975 cell culture than in wild type EGFR A431 cells. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|